Results 241 to 250 of about 117,510 (294)

Personalized Models of Biological Barriers and Their Diseases: Recent Progress with Organs‐On‐Chips

Advanced Biology, Volume 10, Issue 2, February 2026.
Buck and Bugter et al. explore the architectural diversity and physiological functions of human barrier systems and reveal how organ‐on‐chip platforms, particularly those integrating patient‐derived cells, are advancing barrier disease modeling. They highlight how emerging biological and technological advances can be used to bridge the gap between ...
Franziska Buck, Jeroen Bugter, Gizem Yorukoglu, Mina Kazemzadeh Dastjerd, Thomas E. Winkler   +4 more
wiley   +1 more source

The truth behind multiple neuroendocrine tumors: Von Hippel-Lindau syndrome and its diagnostic challenges-A case report and literature review. [PDF]

Sci Prog
Chen Y, Zhou N, He X, Su Y, Xu J, Tang H, Guo D.   +6 more
europepmc   +1 more source

Emerging 2D Materials and Their Hybrid Nanostructures for Label‐Free Optical Biosensing: Recent Progress and Outlook

Advanced Functional Materials, Volume 36, Issue 11, 5 February 2026.
This review highlights recent advances in label‐free optical biosensors based on 2D materials and rationally designed mixed‐dimensional nanohybrids, emphasizing their synergistic effects and novel functionalities. It also discusses multifunctional sensing platforms and the integration of machine learning for intelligent data analysis.
Xinyi Li, Yonghao Fu, Yuehe Lin, Dan Du
wiley   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang   +7 more
wiley   +1 more source

Rare Conditions of Hyperandrogenism Through Lifespan: A Case Series. [PDF]

Case Rep Endocrinol
Apostolopoulou M, Taayedi R, Sărac CP, Demtröder F.   +3 more
europepmc   +1 more source

Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 606-611, February 2026.
Mitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
Annemieke M. Peters van Ton, Nielka P. van Erp, Annenienke C. van de Ven, Janneke E. W. Walraven, Loek A. W. de Jong   +4 more
wiley   +1 more source

Bilateral adrenal tumors presenting with Cushing syndrome in the setting of horseshoe kidney: surgical and urological considerations (case report). [PDF]

Pan Afr Med J
Putra AR, Seputra KP, Budaya TN, Wicaksono HN.   +3 more
europepmc   +1 more source

Association Between Peripheral IL‐6 Levels in the Acute Stage of Stroke and Poststroke Depression: A Systematic Review and Meta‐Analysis

Brain and Behavior, Volume 16, Issue 2, February 2026.
This is a meta‐analysis on the relationship between IL‐6 concentration in the acute phase of stroke and poststroke depression. Higher peripheral IL‐6 concentrations in the acute stage of stroke are closely related to the risk of PSD; collecting samples within 1 day after stroke onset and evaluating depression post discharge are recommended.
Hongmin Gong, Jiaqin Yuan, Min Li, Deqi Xiong, Fayang Ling, Mei Liu, Yan Hu, Shouqiang Wang   +7 more
wiley   +1 more source